Chad, Sarah, Brittany& Linda are all never-smokers with RET-positive #lungcancer. They are parents, siblings, friends & spouses. This is their story. #lcsm@StephenVLiu@NarjustFlorezMD@VivekSubbiah https://t.co/yK80vu7sRZ
Proud to announce our collaboration with @23andme + 19 lung cancer advocacy groups to advance the Lung Cancer Genetics Study. US #lungcancer survivors: pls join & help us drive life-saving scientific discoveries. #lcsm
https://t.co/CAcQMh9BZ1
‼️ #ASCO24 simultaneous publication by Williams et al:
CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced #NSCLC: https://t.co/iTbarTBilu
#ASCO24 Rapid Oral Presentation: Safety and efficacy of a selective RET inhibitor in pediatric and adolescent patients with RET-altered solid tumors.
Results from the phase 1/2 LIBRETTO-121 study: https://t.co/Qsh6kB9k6E
#CancerResearch#PrecisionMedicine
At #ASCO24, see our poster presentation examining a selective RET inhibitor in patients with non-MTC RET-mutated tumors.
Results from the LIBRETTO-001 study: https://t.co/qrA4Iu421j
#CancerResearch#PrecisionMedicine
At #ASCO24, we’re sharing intracranial outcomes data from LIBRETTO-431, a phase 3 study investigating front-line use of a selective RET inhibitor in patients with RET fusion+ advanced #NSCLC.
Read the results here: https://t.co/U9suO5brbK
#CancerResearch#LungCancer#LCSM
Dr. @LeciaSequist with a brilliant #ASCO24 discussion of LAURA and #EGFR NSCLC. Do we apply this paradigm now to subtypes with CNS active agents that have long term safety data like #ALK and #RET? I think so!
Excellent discussion from @LeciaSequist We can’t do the same for all oncogene driven tumours. Worth considering if there is CNS penetration and low tox. Access will be issue. #LCSM#ASCO24
Our latest blog features @TejasPatilMD as he highlights the importance of teamwork in #lungcancerresearch and why his work to study #MET & #EGFR signaling pathways may help us overcome drug resistance in multiple types of lung cancer. https://t.co/Xr8fouruBL #RET#lcsm
Every year since 2018 we have gathered 5 or more year survivors of lung cancer together at CU to show others that hope has a face. This is the May 11th 2024 gathering. Rock on!
Targeting EGFR and MET pathways to overcome resistance to targeted therapies. Thanks to the Hamoui Foundation, Lungevity, Dr. Patil and partners for this exciting research-- potentially relevant for multiple drivers!
https://t.co/nUNEv4hq26
Double-dose osimertinib combined with intrathecal injection of pemetrexed improves the efficacy of EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis: case report and literature review
https://t.co/f9DLjCPelY
In our latest blog, Dr. Hideo Watanabe (@IcahnMountSinai) shares updates on what is happening in his lab that could improve the long-term effectiveness of targeted therapy treatment for #lungcancer patients. Read here: https://t.co/wQxULE2XtB @RETpositive
In our latest blog, Dr. Hideo Watanabe (@IcahnMountSinai) shares updates on what is happening in his lab that could improve the long-term effectiveness of targeted therapy treatment for #lungcancer patients. Read here: https://t.co/wQxULE2XtB @RETpositive
Big news for European #cancer#patients 🇪🇺
Selpercatinib has been approved by @EMA_News for advanced RET fusion positive solid tumours 🎯
This marks the 2nd tumour agnostic, biomarker-driven approval in the EU.
#PrecisionMedicine@OncoAlert 🚨
https://t.co/kYe2kTTrV6
📌Did You Know?
📌The FIRST International Pregnancy and Lung Cancer Registry has been created by the #FlorezLab, to understand the disease in this special population.
📌Anyone, ANYWHERE in the world can enter their own cases
Email us📩: [email protected]